TUMOUR GRADE REGRESSION (TRG) AND CORRELATION WITH MAGNETIC RESONANCE IMAGING (MRI) IN RECTAL CANCER
-
Published:2022-09-01
Issue:
Volume:
Page:11-14
-
ISSN:
-
Container-title:INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
-
language:en
-
Short-container-title:ijsr
Author:
A Ocanto1, Santos Y Dos2, R Cantero3, I Rodríguez4, R Morera1
Affiliation:
1. Department of Radiation Oncology. La Paz University Hospital, Madrid. Spain., Autonomous University of Madrid, Madrid. Spain. 2. Department of Radiology, Segovia General Hospital, Segovia. Spain. 3. Autonomous University of Madrid, Madrid. Spain., Colorectal Unit, Department of Surgery, La Paz University Hospital, Madrid. Spain. 4. Department of Radiation Oncology. La Paz University Hospital, Madrid. Spain.
Abstract
Purpose: Colorectal cancer is the third most common cancer worldwide, neoadjuvant chemoradiotherapy (nCRT) is the standard treatment for
locally advanced rectal cancer (LARC) and Magnetic Resonance Imaging (MRI) plays an important role in the management of this cases,
determining the response to treatment but nowadays does not exist an unique criteria to unify tumour regression grade (TRG) and determinate
possible patients for watch and wait and surgical option. 137 patients: 71 (51,8%) m Method: en and 66 (48,2%) women with newly diagnosis of
LARC underwent to nCRT and evaluate locally with MRI were analyzed to determinate the circumferential resection margin (CRM), extramural
vascular invasion (EMVI), satellite tumour deposit (STD), the state of the sphincter complex (SC) and mrTRG evaluated by experienced
abdominal radiologist. Complete pathological response (cPR) was determinate in Result: 30 patients, 57,5% presented partial pathological
response (pPR), CRM were 26,4%, EMVI were 18,4%, STD were 14,6% and SCI 6,9% all of them with statistical signicative (p<0,05)
relationated with overall survival (OS), mrTRG 1-2 were 43,33% and mrTRG 3-5 40%. MRI is a Conclusion: feasible option to determinate TRG
in patients with LARC underwent to nCRT and mrTRG criteria are the best option to classify these patients and with new biopsy could be the
standard of care for offers watch and wait option to determinate patients, avoiding in many cases surgical option.
Publisher
World Wide Journals
Subject
Water Science and Technology,History,Cultural Studies,Cancer Research,Oncology,Cancer Research,Oncology,Cancer Research,Pharmacology,Oncology,Molecular Medicine,Cancer Research,Genetics,Oncology,General Medicine,Cancer Research,Pharmacology,Cancer Research,Oncology,Cancer Research,Genetics,Oncology,Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference30 articles.
1. Tchelebi LT, Romesser PB, Feuerlein S, Hoffe S, Latifi K, Felder S, Chuong MD. Magnetic Resonance Guided Radiotherapy for Rectal Cancer: Expanding Opportunities for Non-Operative Management. Cancer Control. 2020 Jan-Dec;27(1):1073274820969449. doi: 10.1177/1073274820969449. PMID: 33118384; PMCID: PMC7791447. 2. Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124–5130. 3. Sauer R, Becker H, HohenbergerW, Rödel C,Wittekind C, Fietkau R et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740. 4. Massaras D, Pantiora E, Sotirova E, Dellaportas D, Dafnios N, Zygogianni A, Theodosopoulos T. Neoadjuvant chemoradiotherapy in rectal cancer and anorectal sphincter dysfunction: Review of the literature. J BUON. 2020 Jan-Feb;25(1):35-39. PMID: 32277612 5. Jang JK, Lee JL, Park SH, Park HJ, Park IJ, Kim JH, Choi SH, Kim J, Yu CS, Kim JC. Magnetic resonance tumour regression grade and pathological correlates in patients with rectal cancer. Br J Surg. 2018 Nov;105(12):1671-1679. doi: 10.1002/bjs.10898. Epub 2018 Jun 12. PMID: 29893988.
|
|